The engineering team at Flowonix has a rich history of developing the technology to efficiently deliver medication when a patient needs it most.
Our team continues to innovate and is proud to hold 12 issued patents and an additional 7 patents pending. A leader in the industry, our team has been responsible for many early drug delivery systems, including:
- First implant for anticoagulant Heparin
- First human implant for Floxuridine (FUDR, an anti-cancer chemotherapy drug)
- First human implant for insulin
- First human implant for morphine
- First valve regulated intrathecal pump
- US Patents on:
- Programmable valve pumps
- Implantable, refillable pumps
- Long life power supplies for implantable pumps
- Septumless implantable pumps
- Low power electromagnetic valves
- Pump diagnostic systems
U.S. Patents:
Implantable Pump Connector for Catheter Attachment - 7,452,354
Implantable Pump Connector for Catheter Attachment - 7,927,325
MRI Compatible Programmable Valve Pump -7,828,702
Implantable Refillable Infusion Device - 6,764,472
Implantable Refillable Infusion Device and Septum Replacement Kit - 7,108,686
Two-Way Accumulator Programmable Valve Pump - 8,273,058
Two-Way Accumulator Programmable Valve Pump - 8,696,627
Multiple Reservoir Implantable Drug Infusion Device and Method - 8,545,477
Multiple Reservoir Implantable Drug Infusion Device and Method - 8,551,044
Patent Applications:
Methods and Systems for Providing Metered Doses of a Compound to an Individual - 2011-0060318
Implantable Drug Delivery System Having Periodic Drug Delivery Regimen to Avoid Granulomas - 2010-0152713
Additional non-published patent applications are pending
For more information on Prometra®, contact Flowonix.